[
    [
        {
            "time": "2018-03-15",
            "original_text": "FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs",
            "features": {
                "keywords": [
                    "FDA",
                    "Gottlieb",
                    "drug pricing",
                    "high costs"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Biogen, AbbVie's Zinbryta, yanked from market, connected to three U.S. cases of brain inflammation",
            "features": {
                "keywords": [
                    "Biogen",
                    "AbbVie",
                    "Zinbryta",
                    "brain inflammation",
                    "recall"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biogen, AbbVie's Zinbryta, yanked from market, connected to three U.S. cases of brain inflammation",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Zinbrynta Now Connected To Brain Inflammation",
            "features": {
                "keywords": [
                    "Zinbrynta",
                    "brain inflammation"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Zinbrynta Now Connected To Brain Inflammation",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-05",
            "original_text": "Why Gilead Sciences’ Harvoni Lost Market Share in 4Q17",
            "features": {
                "keywords": [
                    "Gilead Sciences",
                    "Harvoni",
                    "market share",
                    "4Q17"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Why Gilead Sciences’ Harvoni Lost Market Share in 4Q17",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-05",
            "original_text": "Gilead Sciences’ HCV Products: Lower Revenues in 4Q17",
            "features": {
                "keywords": [
                    "Gilead Sciences",
                    "HCV",
                    "revenues",
                    "4Q17"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Gilead Sciences’ HCV Products: Lower Revenues in 4Q17",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-02-20",
            "original_text": "Johnson & Johnson’s Pharmaceutical Segment in 4Q17",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "pharmaceutical segment",
                    "4Q17"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Johnson & Johnson’s Pharmaceutical Segment in 4Q17",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-25",
            "original_text": "Europe's medicines regulator calls for recall of Biogen, AbbVie multiple sclerosis drug",
            "features": {
                "keywords": [
                    "Europe",
                    "regulator",
                    "recall",
                    "Biogen",
                    "AbbVie",
                    "multiple sclerosis"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Europe's medicines regulator calls for recall of Biogen, AbbVie multiple sclerosis drug",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]